UY31280A1 - Oligonucleotidos inmunoestimuladores con un motivo de combinacion con actividad mejorada - Google Patents

Oligonucleotidos inmunoestimuladores con un motivo de combinacion con actividad mejorada

Info

Publication number
UY31280A1
UY31280A1 UY31280A UY31280A UY31280A1 UY 31280 A1 UY31280 A1 UY 31280A1 UY 31280 A UY31280 A UY 31280A UY 31280 A UY31280 A UY 31280A UY 31280 A1 UY31280 A1 UY 31280A1
Authority
UY
Uruguay
Prior art keywords
oligonucleotides
immuno
interferon
useful
improved activity
Prior art date
Application number
UY31280A
Other languages
English (en)
Inventor
Douglas Charles Hanson
Jorg Vollmer
Samulowitz Ulrike
Uhlmann Eugen
Arthur M Krieg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40130811&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY31280(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of UY31280A1 publication Critical patent/UY31280A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se describen oligonucleotidos inmunoestimuladores que contienen un motivo inmonoestimulador CpG y un segundo motivo capaz de formar una estructura secundaria, incluyendo estructuras dobles y de orden superior in vitro e in vivo. Éstos incluyen ácidos nucleicos o sus sales farmacéuticamente aceptables, que tienen secuencias base que incluyen 5?? TCGTCGTTTTCGGCGCGCGCCGT 3??(SEC ID Ns:1), en donde cada C está sin metilar y 3?? del ácido nucleico. Los oligonucleotidos activan las células B y los linfocitos citolíticos naturales e inducen la expresion de interferon de tipo I e interferon-y. Los oligonucleotidos son utiles para tratar una diversidad de trastornos y afecciones que incluyen alergia, asma, infeccion y cáncer. Además de su uso como agentes individuales y como terapias de combinacion, los oligonucleotidos descritos son utiles como adyuvantes en vacunas.
UY31280A 2007-08-13 2008-08-11 Oligonucleotidos inmunoestimuladores con un motivo de combinacion con actividad mejorada UY31280A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US96447707P 2007-08-13 2007-08-13

Publications (1)

Publication Number Publication Date
UY31280A1 true UY31280A1 (es) 2009-03-31

Family

ID=40130811

Family Applications (1)

Application Number Title Priority Date Filing Date
UY31280A UY31280A1 (es) 2007-08-13 2008-08-11 Oligonucleotidos inmunoestimuladores con un motivo de combinacion con actividad mejorada

Country Status (10)

Country Link
US (2) US8198251B2 (es)
EP (2) EP2190440A1 (es)
JP (1) JP2010536335A (es)
AR (1) AR067930A1 (es)
CA (1) CA2696460A1 (es)
CL (1) CL2008002381A1 (es)
PE (1) PE20090985A1 (es)
TW (1) TW200914033A (es)
UY (1) UY31280A1 (es)
WO (1) WO2009022215A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
CN100334228C (zh) * 2001-06-21 2007-08-29 戴纳瓦克斯技术公司 嵌合免疫调制化合物及其使用方法
CA2536139A1 (en) * 2003-09-25 2005-04-07 Coley Pharmaceutical Group, Inc. Nucleic acid-lipophilic conjugates
CN101820908A (zh) * 2007-10-09 2010-09-01 科利制药公司 包含改性糖部分的免疫刺激寡核苷酸类似物
US8119129B2 (en) * 2008-08-01 2012-02-21 Bristol-Myers Squibb Company Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases
CA3033133C (en) 2009-03-25 2021-11-09 The Board Of Regents Of The University Of Texas System Compositions for stimulation of mammalian innate immune resistance to pathogens
US9296803B2 (en) 2010-03-11 2016-03-29 Health Research, Inc. Methods and compositions containing Fc fusion proteins for enhancing immune responses
CN105481983B (zh) 2010-09-09 2021-09-03 辉瑞公司 4-1bb结合分子
WO2016044839A2 (en) 2014-09-19 2016-03-24 The Board Of Regents Of The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
WO2016079899A1 (ja) * 2014-11-20 2016-05-26 国立研究開発法人医薬基盤・健康・栄養研究所 異なる核酸アジュバントの組み合わせによる、新規Ｔｈ１誘導性アジュバントおよびその用途
AU2015374385B2 (en) 2014-12-31 2020-08-06 Checkmate Pharmaceuticals, Inc. Combination tumor immunotherapy
US20180161427A1 (en) * 2015-05-29 2018-06-14 Merck Sharp & Dohme Corp. Combination of an anti-il-10 antibody and a cpg-c type oligonucleotide for treating cancer
EP3436066A1 (en) 2016-04-01 2019-02-06 Checkmate Pharmaceuticals, Inc. Fc receptor-mediated drug delivery
WO2019036855A1 (en) 2017-08-21 2019-02-28 Adagene Inc. ANTI-CD137 MOLECULES AND THEIR USE
EP3746457A1 (en) 2018-01-29 2020-12-09 Stichting Katholieke Universiteit New potent sialyltransferase inhibitors
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
WO2019148444A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Anti-ctla4 antibodies and methods of making and using the same
WO2019160866A2 (en) * 2018-02-13 2019-08-22 Checkmate Pharmaceuticals, Inc. Compositions and methods for tumor immunotherapy
AU2019251421A1 (en) 2018-04-09 2020-10-29 Checkmate Pharmaceuticals Packaging oligonucleotides into virus-like particles
CN113286634A (zh) 2018-05-23 2021-08-20 辉瑞公司 对gucy2c特异性的抗体及其用途
SG11202010580TA (en) 2018-05-23 2020-12-30 Pfizer Antibodies specific for cd3 and uses thereof
IL282368B2 (en) * 2018-10-24 2024-09-01 Hoffmann La Roche A process for the purification of oligonucleotides
US20220370606A1 (en) 2018-12-21 2022-11-24 Pfizer Inc. Combination Treatments Of Cancer Comprising A TLR Agonist
CN115397853A (zh) 2019-12-17 2022-11-25 辉瑞大药厂 对cd47、pd-l1具特异性的抗体及其用途
WO2022094102A1 (en) * 2020-10-30 2022-05-05 Mid-Atlantic Biotherapeutics, Inc. Immunostimulatory oligonucleotides for the prevention and treatment of covid-19
CN117568339A (zh) * 2023-01-19 2024-02-20 华普生物技术(河北)股份有限公司 CpG寡核苷酸及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5177198A (en) 1989-11-30 1993-01-05 University Of N.C. At Chapel Hill Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5859231A (en) 1993-09-03 1999-01-12 Duke University Synthesis of oligonucleotides with boranophosphonate linkages
US6160109A (en) 1995-10-20 2000-12-12 Isis Pharmaceuticals, Inc. Preparation of phosphorothioate and boranophosphate oligomers
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US6207819B1 (en) 1999-02-12 2001-03-27 Isis Pharmaceuticals, Inc. Compounds, processes and intermediates for synthesis of mixed backbone oligomeric compounds
DK1446162T3 (da) * 2001-08-17 2008-12-08 Coley Pharm Gmbh Kombinationsmotiv-immunstimulatoriske oligonukleotider med forbedret aktivitet
US7998492B2 (en) * 2002-10-29 2011-08-16 Coley Pharmaceutical Group, Inc. Methods and products related to treatment and prevention of hepatitis C virus infection
AU2004226605A1 (en) * 2003-04-02 2004-10-14 Coley Pharmaceutical Group, Ltd. Immunostimulatory nucleic acid oil-in-water formulations for topical application
CA2536139A1 (en) * 2003-09-25 2005-04-07 Coley Pharmaceutical Group, Inc. Nucleic acid-lipophilic conjugates
KR101107818B1 (ko) * 2003-10-30 2012-01-31 콜레이 파마시티컬 그룹, 인코포레이티드 향상된 면역자극 효능을 가진 ｃ-부류 올리고뉴클레오티드유사체
DE102004038535B4 (de) * 2004-08-06 2012-10-04 Universitätsklinikum Schleswig-Holstein Zelluläre Einschleusung von Nukleinsäurewirkstoffen
JP2009515896A (ja) * 2005-11-11 2009-04-16 ファイザー・インク 免疫調節性オリゴデオキシヌクレオチドを使用する併用療法
MX2009003398A (es) * 2006-09-27 2009-08-12 Coley Pharm Gmbh Analogos de oligonucleotidos cpg que contienen analogos t hidrofobos con actividad inmunoestimuladora mejorada.

Also Published As

Publication number Publication date
EP2190440A1 (en) 2010-06-02
WO2009022215A8 (en) 2010-03-11
US20120219571A1 (en) 2012-08-30
CL2008002381A1 (es) 2009-02-13
TW200914033A (en) 2009-04-01
PE20090985A1 (es) 2009-08-03
CA2696460A1 (en) 2009-02-19
AR067930A1 (es) 2009-10-28
US8198251B2 (en) 2012-06-12
WO2009022215A1 (en) 2009-02-19
EP2591787A1 (en) 2013-05-15
JP2010536335A (ja) 2010-12-02
US20090087446A1 (en) 2009-04-02

Similar Documents

Publication Publication Date Title
UY31280A1 (es) Oligonucleotidos inmunoestimuladores con un motivo de combinacion con actividad mejorada
ECSP066589A (es) Análogos oligonucleótidos clase c con potencia inmunoestimulante mejorada
PA8791701A1 (es) Imidazopiridinonas
CY1124720T1 (el) Απο του στοματος σκευασματα αναλογων κυτιδινης και μεθοδοι χρησης αυτων
BRPI0618857A8 (pt) Oligonucleotídeo de rna isolado, e método para regular negativamente células reguladoras cd4+ imunossupressoras
DOP2017000175A (es) Dinucleótidos cíclicos útiles en el tratamiento del cáncer
HRP20180282T1 (hr) Imunoterapija na bazi indoleamin 2, 3-dioksigenaze
ECSP10010637A (es) Anticuerpos anti-factor d humanizados y sus usos
GT200500325A (es) Pirazolo-pirimidinas 1,4-sustituidas como inhibidores de quinasa
AR100225A2 (es) Anticuerpos anti-factor d humanizados y usos de los mismos
BRPI0815578B8 (pt) Peptídeo de cdca1, seu uso e composição imunogênica compreendendo o mesmo para induzir imunidade, tratar e/ou prevenir o câncer, bem como método in vitro para induzir uma célula apresentadora de antígeno e uma célula t citotóxica (killer)
BRPI0414867A (pt) pirazolopiridinas e seus análogos
BR0010612A (pt) Vacinas
RU2016122168A (ru) Антисмысловые конъюгаты, направленные на аполипопротеин b
UY29639A1 (es) Amidas sustituidas con heteroarilo que comprenden un grupo enlazador insaturado o cíclico, y su uso como productos farmacéuticos
PE20160158A1 (es) Oligomeros antisentido y conjugados con diana en pcsk9
CO6630139A2 (es) Aptámeros par b-bgf y su uso en el tratamiento de enfermedades y transtornos mediados por b-ngf
ES2340807T3 (es) Oligonucleotidos sinteticos utiles terapeuticamente.
AR068302A1 (es) Peptidos para vacunas para canceres que expresan antigenos asociados con tumores
CY1114643T1 (el) Νεοπλασματικες κυτταρικες σειρες nm-f9 (dsm acc2606) και nm-d4 (dsm acc2605), χρησεις αυτων
AR061930A1 (es) Mimeticuerpos de glp-1 humanos, composiciones, metodos y usos
BR112012013664A2 (pt) rabdovírus oncolítico
BR0211520A (pt) Células apresentando antìgeno, método para preparação da mesma e uso da mesma para vacinas de câncer
CY1114912T1 (el) Εμβολιο για την προληψη της υποτροπης του καρκινου του μαστου
NI201900094A (es) COMPUESTOS DE TIPO IMIDAZO[4, 5-c]QUINOLIN-2-ONA DEUTERADOS Y SU USO EN EL TRATAMIENTO DEL CÁNCER

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20171011